Navigation Links
Revolutionary Immunologic Data Explains Function of Diamyd Diabetes,Vaccine

of insulin producing beta cells by the immune system (the so-called “autoimmune attack”). These immunological markers remained upregulated even 15 months after the first injection, while patients that received placebo showed a downregulation of the same markers over time. Accumulation of scientific evidence has long pointed to GAD65, the active ingredient of Diamyd®, as a possible “immunomodulator” that could prevent the immune system from destroying the insulin producing beta cells.


Immunological Findings Consistent with Expectations Explains Positive Clinical Results
Professor Ludvigsson explained that the immunological data provided direct confirmation of the positive clinical results obtained in August 2006. They demonstrated that treatment close to disease onset provided a better clinical effect than a later in time administration of the vaccine. The new immunological findings indicate that virtually all Diamyd® treated patients, regardless of disease duration, responded immunologically, but that the clinical effect of arresting the autoimmune attack that destroys beta cells close to disease onset is superior to a later intervention when the patient’s beta cells have been almost totally destroyed.

“This may be a breakthrough in diabetes research”, says Professor Johnny Ludvigsson. “There is no doubt that the GAD-vaccine has had positive effects. And it is a treatment that is very simple and without side effects. We have previously reported that the earlier a patient is treated with Diamyd®, the better are the chances that the endogenous insulin production will be preserved. Now we can state that the treatment may be relevant also at a later stage as the immunological effect observed may be a prerequisite to allow beta cell regeneration or transplanted islets or stem cells to thrive without being destroyed by recurrent autoimmune attacks.”

Potentially Groundbreak
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Mild Asthma, a Revolutionary Therapy from Italian Research
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
5. Data Suggest Cymbalta Improved Functioning in Patients with Generalized Anxiety Disorder
6. Early Results of the CellCept Spare the Nephron Study Examine Kidney Function
7. EPIX Pharmaceuticals Announces Statistically Significant Results in Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate
8. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
9. Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of CERE-120 Demonstrating Improved Motor Function in Parkinsons Patients
10. Heart Attack Patients Treated With Novel Stem Cell Therapy Experience Significant Improvement in Heart and Lung Function
11. BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality
Post Your Comments:
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Capecitabine More Than Doubles Time to Progression and Overall Response ... + Placebo in Patients with 2nd or 3rd Line Metastatic ... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) yesterday announced ... Akt-inhibitor for cancer, in combination with capecitabine as a treatment ...
... , New study finds patients who opt for surgery have decreased ... People with the spine disease called degenerative spondylolisthesis ... from pain over time compared to those who do not have ... of The Journal of Bone and Joint Surgery ...
Cached Medicine Technology:Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 2Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 3Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 4Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 5Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 6Back to Normal: Surgery Improves Outcomes for Spine Patients 2Back to Normal: Surgery Improves Outcomes for Spine Patients 3Back to Normal: Surgery Improves Outcomes for Spine Patients 4
(Date:7/10/2014)... far outweigh the risks when children receive The Right ... Dose. However, overuse and misuse of imaging change the ... effort to ensure a national protocol is put into ... of Patient Safety , calls for the American College ... and the Centers for Medicare & Medicaid Services to ...
(Date:7/10/2014)... more severe illness and even death are likely to ... developing influenza. Now, however, a team of researchers based ... reverse the order of infection, the bacteria Streptococcus ... a bad case of the flu. , The ... described as a bacterial virulence factor, might protect macrophagesa ...
(Date:7/10/2014)... Rutgers University-Newark says the human brain operates much the ... that could provide a better understanding of schizophrenia, bipolar ... an estimated 13.6 million Americans. , In newly published ... an assistant professor at the Center for Molecular and ... a person at rest is basically the same as ...
(Date:7/10/2014)... with localized prostate cancer were more likely to ... less effective treatments and survived for shorter times ... a UCLA study has found. , The negative ... such as bias against the mentally ill, depression,s ... lack of investment in his general health and ...
(Date:7/10/2014)... are just as tempting as full-fat equivalents could ... insights into how proteins can replace fats without ... by the Engineering and Physical Sciences Research Council ... University of Edinburgh has produced modified proteins that ... mimic the behaviour of fats during food manufacture. ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2Health News:Working to loosen the grip of severe mental illness 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2
... 5, 2008/Saranac Lake, N.Y.-- On May 12, 2008, the ... in their Distinguished Americans series. The stamp, the eleventh ... (1848-1915). Stamp collecting is one of the most popular ... 20 million American collectors participating in the activity. The ...
... PRINCETON, N.J., May 7 Patients, nurses,physicians and other ... on the State House May 12 to protest the ... 2009 state budget,plan., WHAT: "Care Today, Gone Tomorrow," ... House steps, West State Street, Trenton, WHEN: 12 ...
... from Caring.com Now Available to Thousands ... of Pennsylvanians Caring for an Aging Parent, ... to,announce a partnership with Trib Total Media, publisher of ... the,magazine,s new online companion. The new online resource,( http://pacaregiver.caring.com ...
... HMS Holdings Corp. (Nasdaq:,HMSY) today announced that it ... which will be held May 13-15, 2008 at the ... CEO, and Walter Hosp, Chief Financial,Officer of HMS Holdings ... PT., HMS Holdings Corp. (Nasdaq: HMSY ) ...
... families in Mexico support innovations to extend the local, productive impact of remittances shines ... ... in Mexico and the US. - Broad, support in communities of origin for ... money from the US. -, Family members in Mexico would encourage senders ...
... leads $12 Million in Series A First Tranche Financing, ... NGN Capital announced,today the formation of ACT Biotech Inc., ... cancer drugs. ACT Biotech has,entered into a license agreement ... early stage oncology assets. In conjunction with the,agreement, ACT ...
Cached Medicine News:Health News:New United States Postal Service stamp honors an American scientist 2Health News:New United States Postal Service stamp honors an American scientist 3Health News:Caring.com Partners With Trib Total Media to Support the Development of a New Online Eldercare Resource 2Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 2Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 3Health News:ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare 2
The Spex SkinSkan is the only in-vivo, fibre-optic spectrofluorometer designed specifically for skin-fluorescence measurements. It is also ideal for many remote sensing steady-state fluorescence appl...
The essence of fluorescence analysis is sensitivity. The high throughput optical system in the RF-5301PC employs a blazed holographic grating, photomultiplier and digital signal processing to provide...
The new Gemini EM microplate spectrofluorometer builds on the successful Gemini platform. This next generation reader incorporates all of the high performance features of the Gemini XS with new capab...
... DNA, RNA, Or Fluorescent Tags. Accurate quantitation of ... to life science research. The RF-Mini 150 Fluorometer ... as small as 1ng/ml of DNA specific Hoechst ... and emission filters, the RF-Mini 150 can measure ...
Medicine Products: